Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes
Gianluigi Savarese, MD
James Burton, DM, FRCP
Aaron Wong, MD
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
Summarizing multidisciplinary strategies: Where do we go from here?
The remaining challenges in lowering LDL-c in patients at increased CV risk
Prof. Kausik Ray
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
Julia Brandts, MD
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
Pasquale Perrone-Filardi, MD, PhD
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Ulrich Laufs, MD, PhD
Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target
Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Erin Michos
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
CETP inhibition: Lessons from two decades of clinical trials
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
Managing hypertrophic cardiomyopathy in clinical practice: The patient journey
Perry Elliott, MD
Roberto Barriales-Villa, MD, PhD
Iacopo Olivotto, MD
Updates From the 7th World Symposium Task Force
Eric D. Austin, MD, MSCI
Hilary M. DuBrock, MD
H. James Ford, MD
Gustavo A. Heresi, MD, MS
Gergely Meszaros, JD, MSc
Oksana A. Shlobin, MD
Ioana Preston, MD
Lucilla Piccari, MD, PhD
What are the challenges in making the right diagnosis in HCM?
Understanding the etiology of HCM and pathways for intervention
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.